FOR INTRANASAL ADMINISTRATION BY A HEALTH CARE PROVIDER.
Clinical studies are ongoing with Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal to determine the optimal number of doses.
Available data show that children 9 years of age and younger are largely serologically na√Øve to the pandemic (H1N1) 2009 virus [1]. Based upon these data Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal should be administered as follows:

Each 0.2 mL dose is administered as 0.1 mL per nostril.
Each sprayer contains a single dose; approximately one-half of the contents should be administered into each nostril. Refer to the administration diagram (Figure 1) for step-by-step administration instructions. Once the vaccine has been administered, the sprayer should be disposed of according to the standard procedures for medical waste (e.g., sharps container or biohazard container).
Figure 1 
Note: Active inhalation (i.e., sniffing) is not required by the patient   during vaccine administration
